GlobeNewswire Inc.··Not SpecifiedCalidi Biotherapeutics Advances Tumor-Targeted BiTE Platform Toward Clinical Development
Calidi Biotherapeutics advances RedTail virotherapy platform combining BiTE and IL-15 therapies for solid tumors, aiming to overcome immunosuppressive microenvironments. IND submission planned for 2026.
CLDIsolid tumorsRedTail platform